PONESIMOD (Ponvory®)

Clinical Indication

Relapsing forms of multiple sclerosis with active disease.

Comments

In line with NICE TA767

Implementation date 2nd May 2022

Date of classification

September 2021

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.